A Phase I, Single-Dose, Open-Label Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of APL-2

Trial Profile

A Phase I, Single-Dose, Open-Label Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of APL-2

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Jul 2017

At a glance

  • Drugs APL 2 (Primary)
  • Indications Dry age-related macular degeneration; Ischaemia; Paroxysmal nocturnal haemoglobinuria; Wet age-related macular degeneration
  • Focus Pharmacokinetics
  • Acronyms AIRIS
  • Most Recent Events

    • 08 Jul 2017 Planned initiation date changed from 3 Jul 2017 to 11 Jul 2017.
    • 06 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top